RecruitingNCT07116772

Serial Assessment of Fertility Experiences

A Prospective Longitudinal Study of Growth, Development, Fertility and Reproductive Outcomes Among Adolescents and Young Adults With Sickle Cell Anemia With Hydroxyurea

Sponsor

Children's Hospital Medical Center, Cincinnati

Enrollment

250 participants

Start Date

Jul 10, 2023

Study Type

OBSERVATIONAL

Conditions

Sickle Cell Anemia

Summary

The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.

Eligibility

Min Age: 8 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with sickle cell anemia. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 8 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.